Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADJUST: Adjustable versus standard brodalumab dosing in high-body-weight plaque psoriasis
2023-509668-11-00Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 4, randomised, double-blind trial of brodalumab in plaque psoriasis (2 arms), sponsored by LEO Pharma. Primary endpoint: PASI 90 response at Week 40. Started Jun 2022; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-509668-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509668-11-00.